Kagocel 12mg tbl N10

Manufacturer: Ниармедик Плюс ООО/Пр.Ниармедик Фарма ООО
Product is available in pharmacies:
Choose a pharmacy where you would like to pick up the goods
275,50 rub.
+ 6 bonuses на карту
- +
Add to cart
All products in the order are reserved for 24 hours,
after that the order is automatically canceled
Brief information

Производитель

Ниармедик Плюс ООО/Пр.Ниармедик Фарма ООО

The appearance of the product may differ from the photos on the site.

General description
Источник: РЛС

Composition

Pills 1 table.
active substance:  
Kagocel 12 mg
excipients: potato starch-10 mg; calcium stearate-0.65 mg; Ludipress (lactose monohydrate, povidone (Collidone 30), crospovidone (Collidone CL) - to obtain a tablet weighing 100 mg  

Description of the dosage form

Tablets: from white with a brown tint to light brown, round, biconvex, with brown inclusions.

Pharmacokinetics

After 24 hours after administration to the body, the drug Kagocel accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are found in adipose tissue, heart, muscles, testes, brain, and blood plasma. The low content of kagocel in the brain is explained by the high molecular weight of the drug, which makes it difficult to penetrate the BBB. In blood plasma, the drug is mainly in a bound form.

With daily repeated administration of kagocel V d of the drug varies widely in all the studied organs. Especially pronounced accumulation of the drug in the spleen and lymph nodes. When taken orally, about 20% of the administered dose of the drug enters the General bloodstream. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids-47%, with proteins-37%. The unbound portion of the drug is about 16%.

Excretion: the drug is excreted mainly through the intestines: after 7 days after administration, 88% of the administered dose is excreted from the body, including 90% - through the intestines and 10% - by the kidneys. The drug was not detected in the exhaled air.

Pharmacodynamics

The main mechanism of action of the drug Kagocel (hereinafter referred to as Kagocel) is the ability to induce interferon production. Kagocel causes the formation of so-called late interferons in the human body, which are a mixture of alpha and beta interferons with high antiviral activity. Kagocel causes interferon production in almost all cell populations that participate in the body's antiviral response: T - and B - lymphocytes, macrophages, granulocytes, fibroblasts, and endothelial cells. When ingesting a single dose of Kagocel, the titer of interferons in the blood serum reaches its maximum values after 48 hours.

The interferon response of the body to the introduction of kagocel is characterized by a long (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of accumulation of interferons in the intestine when ingesting kagocel does not coincide with the dynamics of titers of circulating interferons. In the blood serum, the production of interferons reaches high values only 48 hours after ingestion of kagocel, while in the intestine, the maximum production of interferons is observed after 4 hours.

The drug Kagocel, when prescribed in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, is not carcinogenic and does not have an embryotoxic effect.

The greatest effectiveness in the treatment of Kagocel is achieved when it is prescribed no later than 4 days from the beginning of acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the pathogen.

Indications of the drug

prevention and treatment of influenza and other acute respiratory viral infections in adults and children aged 3 years and older;

treatment of herpes in adults.

Contraindications

hypersensitivity to the drug components;

lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

pregnancy;

lactation;

age up to 3 years.

Use during pregnancy and lactation

Due to the lack of necessary clinical data, Kagocel is contraindicated during pregnancy and lactation.

Dosage and administration

Inside, regardless of food intake.

For the treatment of influenza and SARS, adults are prescribed 2 tables in the first 2 days. 3 times a day, for the next 2 days-1 table. 3 times a day. Total for the course of treatment - 18 tables. the course duration is 4 days.

Prevention of influenza and SARS in adults is carried out in 7-day cycles: 2 days for 2 tables. 1 time a day, 5 days break, then repeat the cycle. The duration of the preventive course is from 1 week to several months.

For the treatment of herpes in adults, 2 tables are prescribed. 3 times a day for 5 days. Total for the course of treatment - 30 tables. the course duration is 5 days.

For the treatment of influenza and SARS, children from 3 to 6 years are prescribed 1 table in the first 2 days. 2 times a day, in the next 2 days-1 table. 1 time per day. Total for the course — 6 tables. the course duration is 4 days.

For the treatment of influenza and SARS, children from 6 years of age are prescribed 1 table in the first 2 days. 3 times a day, for the next 2 days-1 table. 2 times a day. Total for the course — 10 tables. the course duration is 4 days.

Prevention of influenza and SARS in children from 3 years is carried out in 7-day cycles: 2 days for 1 table. 1 time a day, 5 days break, then repeat the cycle. The duration of the preventive course is from 1 week to several months.

Side effect

Allergic reactions may develop.

If any of the side effects specified in the instructions are aggravated, or the patient has noticed any other side effects not specified in the instructions, you should inform your doctor.

Interaction

Kagocel is well combined with other antiviral drugs, immunomodulators and antibiotics (additive effect).

Overdose

In case of accidental overdose, it is recommended to prescribe copious drinking, cause vomiting.

Special instruction

To achieve a therapeutic effect, the drug should be started no later than 4 days after the onset of the disease.

Influence on the ability to drive vehicles, mechanisms. The effect of the drug on the ability to control vehicles and mechanisms has not been studied.

Form release

Tablets, 12 mg.10 table. in contour cell packaging made of PVC/pvdh film and aluminum foil with heat-sealable coating. 1, 2 or 3 contour cell packages are placed in a pack.

Conditions of supply of pharmacies

Without a prescription.

Manufacturer

1. NIARMEDIC PLUS LLC. 12, Mikoyan Aviakonstruktora str., Moscow, 125252, Russia.

Address of the place of production: 18, Gamalei str., Moscow, 123098, Russia. 4, 10, 11, 18, 33.

2. Chemopharm LLC. 62, Kievskoe shosse, Obninsk, Kaluga region, Russia, 249030.

3. NIARMEDIC PHARMA LLC. 4 Koroleva str., Obninsk, Kaluga region, Russia, 249030, of. 402.

Address of the place of production: 249010, Russia, Kaluga region, Borovsky district, der. Malanino, Kievskoe sh., 120, p. 3, 4, 5.

Legal entity in whose name the registration certificate was issued: niarmedic PLUS LLC. 12, Mikoyan Aviakonstruktora str., Moscow, 125252, Russia.

Send consumer complaints to the address: 12, Aviakonstruktora Mikoyan str., Moscow, 125252, Russia.

Tel. / Fax: (495) 385-80-08.

e-mail: safety@nearmedic.ru

The appearance of the product may differ from the photos on the site.

Information about prescription drugs is for professionals only. The information provided should not be used by patients to make an independent decision on the use of the presented drugs and cannot serve as a substitute for a full-time consultation with a doctor.

A description of the active substances of the drug is provided. The scientific information provided is generalized and cannot be used to decide on the possibility of using a specific drug.

To the top